Floatz logo

Deglycosylated Ricin A Chain-Conjugated Anti-CD19

Recurrent Adult Acute Lymphoblastic Leukemia

Albert Einstein College of MedicinePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

74 Active assets in the Recurrent Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

Deglycosylated Ricin A Chain-Conjugated Anti-CD19 is also rated in:

B-cell adult acute lymphocytic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
leukemiaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →